Adam focuses on representing registered investment companies, both open- and closed-end funds, and investment advisers in regulatory, transactional and compliance matters. On a regular basis he provides advice regarding the creation, registration and operation of new and existing investment products designed for institutional or retail investors. He also works with clients to respond to new SEC rules affecting the investment management industry.

Prior to attending law school, Adam pursued graduate studies in the Chemistry Department at MIT where he focused on biological chemistry. His research focused on cancer-related mechanisms of DNA damage and repair and platinum-based anti-tumor therapeutics.

Adam was also a consultant for a global professional services firm where he assisted with the merger of two major U.S. pharmaceutical companies.